<DOC>
	<DOCNO>NCT01314599</DOCNO>
	<brief_summary>Phase I Study PM01183 Patients Advanced Acute Leukemia determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 .</brief_summary>
	<brief_title>Clinical Study PM01183 Patients With Acute Leukemia Relapsed/Refractory Myelodysplastic Syndrome</brief_title>
	<detailed_description>Open-Label , Dose-Escalating , Clinical Pharmacokinetic Phase I Study PM01183 Patients Advanced Acute Leukemia determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 administer 1-hour intravenous ( i.v . ) infusion three consecutive day ( Days 1-3 ) patient advance acute leukemia ass safety profile tolerability , obtain preliminary information efficacy characterize pharmacokinetics ( PK ) pharmacogenomic ( PGx ) profile PM01183 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Voluntarily sign date write informed consent Age ≥ 18 year . Patients must previous cytological histological diagnosis : Relapsed primary refractory nonM3 acute myeloid leukemia ( AML ) World Health Organization ( WHO ) criterion ( irrespective number prior regimen ) , either de novo secondary [ i.e. , secondary myelodysplastic syndrome ( MDS ) , myeloproliferative neoplasms previous chemotherapy another condition ] . Untreated AML patient ≥ 65 year age , patient candidate standard induction chemotherapy poor risk AML ( i.e. , secondary AML AML adverse cytogenetics complex karyotype ) . Accelerated blastic phase chronic myeloid leukemia ( CML , progressive disease despite treatment BCRABL kinase inhibitor ) , chronic myelomonocytic leukemia ( CMML ) . Relapsed refractory acute lymphoblastic leukemia ( ALL ) WHO criteria . Patients must follow laboratory value prior start treatment : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) range value , unless due elevate indirect bilirubin ( e.g. , Gilbert 's syndrome hemolysis ) . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN . Alkaline phosphatase ( AP ) ≤ 2.5 x ULN . Albumin ≥ 2.5 g/dl . Calculated creatinine clearance ( CrCl ) ≥ 30 ml/min ( use Cockcroft Gault 's formula ) . Creatine phosphokinase ( CPK ) ≤ 2.5 x ULN . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . Negative pregnancy test woman childbearing potential . Pregnant lactating woman ; men woman reproductive potential use effective contraceptive method throughout treatment period six month discontinuation treatment . Patients plan undergo allogeneic BM transplantation within four week . Other relevant disease adverse clinical condition : History presence unstable angina , myocardial infarction , congestive heart failure , clinically significant valvular heart disease within last year . Symptomatic unstable cardiac arrhythmia , and/or prolong QTQTc grade ≥ 2 . History significant neurological psychiatric disorder may affect patient 's compliance protocol assessment . Active uncontrolled infection . Myopathy clinical situation cause significant persistent elevation CPK ( &gt; 2.5 x ULN two different determination perform one week apart ) . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . Hematopoietic allogeneic stem cell transplantation within last four month and/or active graft versus host disease , prior autologous transplantation within last four week . Patients know human immunodeficiency virus ( HIV ) positive . Cytotoxic chemotherapy within last two week ; radiation therapy within last two week ; biologic agent , include hematopoietic growth factor , within last week ; hydroxyurea , imatinib , corticosteroid arsenic trioxide discontinue least 24 hour prior first study drug administration . Treatment investigational product ≤ 5 halflives period prior inclusion study , 30 day therapy ( case unknown halflife ) , unless evidence rapid proliferate disease upon discussion Sponsor . Known hypersensitivity component drug product ( DP ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>lurbinectedin</keyword>
	<keyword>PM01183</keyword>
	<keyword>Pharma Mar</keyword>
	<keyword>Acute Leukemia Relapse Primary Refractory</keyword>
</DOC>